Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo

British Journal of Pharmacology

Volumn 121, Issue 3, 1997, Pages 540-546

  Lewis, E J ^a   Bishop, J ^a   Bottomley, K M K ^a   Bradshaw, D ^a   Brewster, M ^a   Broadhurst, M J ^a   Brown, P A ^a   Budd, J M ^a   Elliott, L ^a   Greenham, A K ^a   Johnson, W H ^a   Nixon, J S ^a   Rose, F ^a   Sutton, B ^a   Wilson, K ^a  

^a ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Arthritis; Cartilage explants; Cartilage protection agent; Collagenase inhibitor; Matrix metalloproteinases; Pharmacokinetics

Indexed keywords

CIPEMASTAT; COLLAGENASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; INTERLEUKIN 1ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE; CATTLE; COLLAGEN DEGRADATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG STRUCTURE; FEMALE; IMPLANT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONARTHRITIS; NONHUMAN; NOSE CARTILAGE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; RAT;

ADMINISTRATION, ORAL; ANIMALS; ARTHRITIS, EXPERIMENTAL; CARTILAGE; CATTLE; COLLAGENASES; HUMANS; IMIDAZOLES; MALE; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 8244221001     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701150     Document Type: Article

References (37)

1. ANTHONY, D., SAVAGE, F., HEMBRY, R. & BOULOS, P. (1994). Protease expression in experimental colitis. Agents Actions, 41 (Special Conference Issue), C201-C203.
2. BARNETT, J., STRAUB, K., NGUYEN, B., CHOW, J., SUTTMAN, R., THOMPSON, K., TSING, S., BENTON, P., SCHATZMAN, R., CHEN, M. & CHAN, H. (1994). Production, purification, and characterisation of human Matrilysin (PUMP) from recombinant Chinese hamster ovary cells. Prot. Express. Purif., 5, 27-33.
3. BECKETT, P.R., DAVIDSON, A.H., DRUMMOND, A.H., HUXLEY, P. & WHITTAKER. M. (1996). Recent advances in matrix metalloproteinase inhibitor research. Drug Discovery Today, 1, 16-26.
4. BIRCHALL, A.M., BISHOP, J., BRADSHAW, D., CLINE, A., COFFEY, J., ELLIOT, L.H., GIBSON, V., GREENHAM, A.K., HALLAM, T.J., HARRIS, W., HUTCHINGS, A., LAMONT, A.G., LAWTON, G., LEWIS, E.J., MAW, A., NIXON, J.S., POLE, D., WADSWORTH, J. & WILKINSN, S.E. (1994). Ro 32-0432, a selective and orally active inhibitor of protein kinase C, prevents T-cell activation. J. Pharmacol. Exp. Ther., 268, 922-929.
5. BIRKEDAL-HANSEN, H., MOORE, W.G.I., BODEN, M.K., WINDSOR, L.J., BIRKEDAL-HANSEN, B., DECARLO, A. & ENGLER, J.A. (1993). Matrix metalloproteinases: a review. Critical Rev. Oral Biol. 4, 197-250.
6. BISHOP. J., GREENHAM, A.K. & LEWIS, E.J. (1993). A novel in vivo model for the study of cartilage degradation. J. Pharmacol. Toxicol. Methods, 30, 19-25.
7. BODE, W., REINEMER, P., HUBER, R., KLEINE, T., SCHNIERER, S. & TSCHESCHE, H. (1994). The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J., 13, 1263-1269.
8. BORKAKOTI, N. (1997). Zinc endoproteinases: a structural superfamily. Structure-based drug design. In Methods and Principles in Medicinal Chemistry, ed. Gubernator, K. & Boehm, V.C.H. Weinheim.
9. BORKAKOTI, N., WINKLER, F.K., WILLIAMS, D.H., D'ARCY, A., BROADHURST, M.J., BROWN, P.A., JOHNSON, W.H. & MURRAY, E.J. (1994). Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Nat. Struct. Biol., 1, 106-110.
10. BOTTOMLEY, K., BORKAKOTI, N., BRADSHAW, D., BROWN, P.A., BROADHURST, M.J., BUDD, J., ELLIOTT, L., EYERS, P., HALLAM, T.J., HANDA, R., HILL, C., JAMES, M., LAHM, H-W., LAWTON, G., MERRITT, J.E., NIXON, J.S., ROTHLISBERGER, U., WHITTLE, A. & JOHNSON, W.H. (1997). Inhibition of bovine nasal cartilage breakdown by selective inhibitors of matrix metalloproteinases. Biochem. J., (in press).
11. BRINCKERHOFF, C.E. (1991). Joint destruction in arthritis: metalloproteinase in the spotlight. Arthritis Rheum., 34, 1073-1075.
12. CONAGHAN, P.G. & BROOKS, P. (1995). Disease-modifying anti-rheumatic drugs, including methotrexate, gold, antimalarials and D-penicillamine. Current Opinion Rheumatol., 7, 167-173.
13. DIOSZEGI, M., CANNON, P. & VAN WART, H.E. (1995). Vertebrate collagenases. Methods Enzymol., 248, 413-431.
14. FELL, H.B., BARRATT, M.E.J., WELLAND, H. & POOL, A.R. (1976). The capacity of pig articular cartilage in organ culture to regenerate after breakdown induced by complement-sufficient antiserum to pig erythrocytes. Calcif. Tiss. Res., 20, 3-21.
15. FREIJE, J.M.P., DIEZ-ITZA, I., BALBIN, M., SANCHEZ, L.M., BLASCO, R., TOLIVIA, J. & LOPEZ-ORTIN, C. (1994). Molecular cloning and expression of collagenase 3 - a novel human matrix metalloproteinase produced by breast carcinomas. J. Biol. Chem., 269, 16766-16773.
16. GUBLER, U., CHUA, A.O., STERN, A.S., HELLMANN, C.P., VITEK, M.P., DECHIARA, T.M., BENJAMIN, W.R., COLLIER, K.J., DUKOVlCH, M., FAMILLETTI, P.C., FIELDER-NAGY, C., JENSON, J., KAFFKA, K., KILIAN, P.C., STREMLO, D., WITTREICH, B.H., WOEHLE, D., MIZEL, S.B. & LOMEDICO, P.T. (1986). Recombinant interleukin-1α: Purification and biological characterisation. J. Immunol., 136, 2492-2497.
17. HARDINGHAM, T.E. (1988). Biosynthesis, assembly and turnover of cartilage proteoglycans. In Research Monographs in Cell and Tissue Physiology. Vol. 15, ed. Glavert A.M., pp. 41-52. Amsterdam: Elsevier.
18. ITO, A. & NAGASE, H. (1988). Evidence that human rheumatoid synovial matrix metalloproteinase-3 is an endogenous activator of procollagenase. Arch. Biochem. Biophys., 267, 211-216.
19. JOHNSON, W.H., ROBERTS, N.A. & BORTAKOTI, N. (1987). Collagenase inhibitors; their design and potential therapeutic use. J. Enzyme. Inhib., 2, 1-22.
20. JOHNSON-WINT, B. (1980). A quantitative collagen film collagenase assay for large numbers of samples. Analyt. Biochem., 104, 175-181.
21. KNIGHT, C.G., WILLENBROCK, F. & MURPHY, G. (1992). A novel courmarin-labelled peptide for sensitive continuous assays of matrix metalloproteinase. FEBS Lett., 296, 263-266.
22. KRANE, S.M. (1974). Joint erosion in rheumatoid arthritis. Arth. Rheum., 17, 306-312.
23. KRANE, S.M., AMENTO, E.P., GOLDRING, M.B., GOLDRING, S.R & STEPHENSON, M.L. (1988). Modulation of matrix synthesis and degradation in joint inflammation. In Research Monographs in Cell and Tissue Physiology, Vol. 15, ed. Glavert A.M. pp. 179-195. Amsterdam: Elsevier.
24. KWOK-CHU, H. & CHI-PUI, P. (1989). Automated analysis of urinary hydroxyproline. Clin. Chim. Acta, 185, 191-196.
25. LEWIS, E.J., BISHOP, J., BOTTOMLEY, K., BRADSHAW, D., BROADHURST, M., BROWN, P., GREENHAM, A.K., HALLAM, T. JOHNSON, W., LAWTON, G. & NIXON, J.S. (1993). Efficacy of Ro 31-9790, an orally active collagenase inhibitor, in animal models of arthritis. Rev. Esp. Rheumatol., 20. Suppl 1, 494.
26. LEWIS, E.J., BISHOP, J., BOTTOMLEY, K.M., BRADSHAW, D., BROWN, P.A., BROADHURST, M.J., BUDD, J.M., ELLIOT, L., GIBSON, V.M., GREENHAM, A.K., HILL, C.H., JOHNSON, W.H., LAWTON, G. & NIXON, J.S. (1996). Efficacy of the cartilage protective agent (Ro 32-355) in in vitro and in vivo models of cartilage degradation. Br. J. Pharmacol., 119, 188P.
27. MOORE, W.M. & SPILBURG, C.A. (1986). Purification of human collagenases with a hydroxamic acid affinity column. Biochemistry, 25, 5189-5195.
28. NIXON, J.S., BOTTOMLEY, K.M.K., BROADHURST, M.J., BROWN, P.A., JOHNSON, W.H., LAWTON, G., MARLEY, J., SEDGWICK, A.D. & WILKINSON, S.E. (1991). Potent collagenase inhibitors prevent interleukin-1-induced cartilage degradation in vitro. Int. J. Tiss. Reac., 13, 237-243.
29. PETTIPHER, E.R., HIGGS, G.A. & HENDERSON, B. (1986). Interleukin-1 induces leukocyte infiltration and cartilage degradation in the synovial joint. Proc. Natl. Acad. Sci. U.S.A., 83, 8749-8753.
30. QUINN, C.O., SCOTT, D.K., BRINCKERHOFF, C.E., MATRISAN, L.M., JEFFREY, J.J. & PARTRIDGE, N.C. (1990). Rat collagenase: cloning, amino acid sequence comparison, and parathyroid hormone regulation in osteoblastic cells. J. Biol. Chem., 265, 22342-22347.
31. SCOTT, D.L. & BACON, P.A. (1985). Joint damage in rheumatoid arthritis: radiological assessments and the effects of anti-rheumatic drugs. Rheumatology Int., 5, 193-199.
32. STETLER-STEVENSON, W.G., LIOTTA, L.A. & KLEINER, D.E. (1993). Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J., 7, 1434-1441.
33. SUTTON, B., HORSPOOL, F., BRYSON, A., BURDEN, D., HEEPS, G., MlTCHELL, A., HOOPER, H., ANGUS, D., SHARP, S. & HARRIS, S. (1996). Pharmacokinetics and metabolism of a new cartilage protective agent. Br. J. Pharmacol., 119, 187P.
34. TRIMBLE, B.S., EVERS, C.J., BALLARON, S.A. & YOUNG, J.M. (1987). Intra-articular injection of Propionibacterium acnes causes an erosive arthritis in rats. Agents Actions, 21, 281-283.
35. WARD, R.V., HEMBRY, R.M., REYNOLDS, J.J. & MURPHY, G. (1991). The purification of tissue inhibitor of matrixmetalloproteinase-2 from its 72 kDa progelatinase complex. Biochem. J., 278, 179-187.
36. WELCH, A.R., HOLMAN, C.M., BROWNER, M.F., GEHRING, M.R., KAN, C.C. & VAN WARTH, E. (1995). Purification of human matrilysin produced in Esherichia coli and characterisation using a new optimised fluorogenic peptide substrate. Arch. Biochem. Biophys., 324, 59-64.
37. WOESSNER, J.F. Jr. (1991). Matrix metalloproteinases and their inhibitors in connective tissue. FASEB J., 5, 2145-2154.